Table 3.
Multivariable logistic regression analyses for the probability of receiving systemic treatment (including chemoradiotherapy) in EAC, ESCC, and GAC patients
| Characteristics | EAC (n = 3077) |
ESCC (n = 794) |
GAC (n = 1836) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | |||||||
| Gender | ||||||||||||
| Men | Referent | Referent | Referent | |||||||||
| Women | 0.86 (0.69 to 1.06) | .16b | 0.81 (0.57 to 1.14) | .23c | 0.79 (0.62 to 1.00) | .046d | ||||||
| Age | 0.93 (0.92 to 0.94) | <.001 | 0.94 (0.92 to 0.96) | <.001 | 0.91 (0.91 to 0.93) | <.001 | ||||||
| Performance status | ||||||||||||
| 0-1 | Referent | <.001 | Referent | <.001 | Referent | <.001 | ||||||
| ≥2 | 0.18 (0.14 to 0.23) | 0.28 (0.17 to 0.44) | 0.29 (0.21 to 0.40) | |||||||||
| Unknown | 0.29 (0.24 to 0.34) | 0.21 (0.14 to 0.32) | 0.24 (0.19 to 0.31) | |||||||||
| No. of comorbidities | ||||||||||||
| 0 | Referent | .004 | Referent | .80 | Referent | <.001 | ||||||
| 1 | 0.88 (0.74 to 1.06) | 0.95 (0.65 to 1.39) | 0.99 (0.77 to 1.28) | |||||||||
| ≥2 | 0.65 (0.53 to 0.82) | 0.79 (0.49 to 1.27) | 0.55 (0.39 to 0.78) | |||||||||
| Unknown | 1.07 (0.72 to 1.57) | 1.04 (0.45 to 2.33) | 0.57 (0.34 to 0.94) | |||||||||
| Lauren classification | ||||||||||||
| Intestinal | Referent | .01 | N/A | — | Referent | .45 | ||||||
| Diffuse | 0.73 (0.57 to 0.93) | — | 0.85 (0.64 to 1.14) | |||||||||
| Mixed | 1.24 (0.67 to 2.34) | — | 0.74 (0.39 to 1.38) | |||||||||
| Indeterminate | 0.81 (0.50 to 1.34) | — | 0.45 (0.12 to 1.65) | |||||||||
| Unknown | 0.75 (0.63 to 0.90) | — | 0.80 (0.60 to 1.07) | |||||||||
| Stage | ||||||||||||
| cT4bM0 | 0.93 (0.45 to 2.07) | 1.26 (0.70 to 2.28) | 0.73 (0.43 to 1.25) | |||||||||
| cM1 | Referent | .87 | Referent | .43 | Referent | .25 | ||||||
| Hospital volumea | ||||||||||||
| Q1 | 0.76 (0.57 to 1.00) | 0.55 (0.29 to 1.05) | 0.93 (0.63 to 1.38) | |||||||||
| Q2 | 1.12 (0.89 to 1.40) | 0.43 (0.26 to 0.72) | 1.24 (0.92 to 1.66) | |||||||||
| Q3 | 1.15 (0.93 to 1.40) | 0.75 (0.51 to 1.10) | 0.81 (0.61 to 1.07) | |||||||||
| Q4 | Referent | .03 | Referent | .007 | Referent | .07 | ||||||
| Extraregional lymph node metastases | 0.90 (0.76 to 1.07) | .22 | 1.11 (0.71 to 1.70) | .63 | 0.82 (0.62 to 1.08) | .16 | ||||||
| Liver metastases | 1.20 (1.03 to 1.43) | .046 | 1.04 (0.66 to 1.61) | .88 | 1.10 (0.83 to 1.48) | .50 | ||||||
| Peritoneal metastases | 0.74 (0.57 to 0.98) | .04 | 0.63 (0.20 to 1.97) | .43 | 0.85 (0.64 to 1.13) | .26 | ||||||
| Lung metastases | 0.91 (0.74 to 1.10) | .32 | 0.73 (0.48 to 1.10) | .14 | 0.91 (0.63 to 1.31) | .60 | ||||||
| Bone metastases | 0.81 (0.62 to 1.00) | .05 | 0.44 (0.25 to 0.78) | .004 | 0.55 (0.35 to 0.86) | .009 | ||||||
| Other metastases locations | 0.61 (0.48 to 0.77) | <.001 | 0.58 (0.31 to 1.09) | .09 | 1.10 (0.78 to 1.57) | .59 | ||||||
Volume of hospital of diagnosis. Per hospital, the volume of gastroesophageal cancer patients diagnosed with gastroesophageal cancer between 2015 and 2018 was calculated. Subsequently, hospitals were categorized into quartiles (Q1-4) according to these volumes, which resulted in hospitals in which less than 25 (Q1), 25-61 (Q2), 61-140 (Q3), and over 140 (Q4) patients were diagnosed in 2015-2018. CI = confidence interval; cM1 = metastatic; EAC = esophageal adenocarcinoma; ESCC = esophageal squamous cell carcinoma; GAC = gastric adenocarcinoma; OR = odds ratio.
Likelihood-ratio tests comparing the full model and the full model without gender: EAC: χ2 = 1.95, 2-sided P = .16.
Likelihood-ratio tests comparing the full model and the full model without gender: ESCC: χ2 = 1.47, 2-sided P = .23.
Likelihood-ratio tests comparing the full model and the full model without gender: GAC: χ2 = 4.01, 2-sided P = .045.